Edition:
United Kingdom

Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

59.64USD
17 Nov 2017
Change (% chg)

$0.01 (+0.02%)
Prev Close
$59.63
Open
$59.64
Day's High
$60.03
Day's Low
$59.23
Volume
86,787
Avg. Vol
161,012
52-wk High
$72.66
52-wk Low
$39.25

Latest Key Developments (Source: Significant Developments)

Agios presents updated phase 1 data from dose expansion cohort of ivosidenib
Friday, 17 Nov 2017 

Nov 17 (Reuters) - Agios Pharmaceuticals Inc :Agios presents updated phase 1 data from dose expansion cohort of ivosidenib (AG-120) in patients with IDH1 mutant positive glioma.Agios Pharmaceuticals Inc - ‍ivosidenib well-tolerated in patients with low grade glioma​.Agios Pharmaceuticals Inc - ‍additional preclinical data demonstrate that ivosidenib and AG-881 suppress 2-HG levels in brain tumor mouse models​.Agios Pharmaceuticals Inc - ‍there were 5 patients with serious adverse events (SAE) and all were deemed unrelated to study treatment​.Agios Pharmaceuticals - ‍preliminary data suggest that both molecules suppress oncometabolite D-2-hydroxyglutarate in an orthotopic brain tumor model​.Agios Pharmaceuticals - study ‍to refine imaging methodology, assess biological effects of IDH inhibitors in perioperative study planned for H1 of 2018​.  Full Article

Agios reports Q3 revenue $11.4 million
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Agios Pharmaceuticals Inc :Agios reports third quarter 2017 financial results.Q3 revenue $11.4 million versus I/B/E/S view $9.8 million.Agios Pharmaceuticals Inc - Qtrly ‍net loss per share $1.59.  Full Article

Agios Pharmaceuticals Inc Q1 net loss was $66.2 million
Thursday, 4 May 2017 

May 4 (Reuters) - Agios Pharmaceuticals Inc :Agios reports first quarter 2017 financial results.Agios Pharmaceuticals Inc - net loss for quarter ended March 31, 2017 was $66.2 million, compared to a net loss of $23.2 million for quarter ended March 31, 2016.Agios Pharmaceuticals Inc - collaboration revenue was $10.5 million for quarter ended March 31, 2017, compared to $31.3 million.  Full Article

Agios Pharmaceuticals appoints Andrew Hirsch as chief financial officer
Tuesday, 16 Aug 2016 

Agios Pharmaceuticals Inc : Appoints Andrew Hirsch as chief financial officer . Glenn Goddard, senior vice president of finance, will be leaving company at end of September to pursue other opportunities .Andrew Hirsch most recently served as president and chief executive officer of Bind Therapeutics.  Full Article

Agios Pharmaceuticals reports qtrly loss per share $1.47
Thursday, 4 Aug 2016 

Agios Pharmaceuticals Inc : Agios reports second quarter 2016 financial results . Collaboration revenue was $7.0 million for quarter ended June 30, 2016, compared to $13.2 million for comparable period in 2015 .Qtrly loss per share $1.47.  Full Article

Agios sees 2016 ending cash position of more than $390 mln
Tuesday, 17 May 2016 

Agios Pharmaceuticals Inc : Agios updates 2016 financial guidance . Expects 2016 ending cash position of more than $390 million .Expects that its cash would be sufficient to fund its operating expenses and capital expenditure requirements through mid-2018.  Full Article

Agios Pharmaceuticals, Celgene establish new collaboration in metabolic immuno-oncology
Tuesday, 17 May 2016 

Agios Pharmaceuticals Inc : Agios and Celgene establish new collaboration in metabolic immuno-oncology and amend certain rights from 2010 agreement . Agios to receive $200 million upfront payment . Ag-120 rights outside United States transferred to Agios . Companies modified certain rights from their 2010 collaboration . As of August 15, 2016, neither party will have financial or other obligations to each other related to AG-120 . After expiration of discovery phase of 2010 agreement, other cancer metabolism programs discovered at co will remain owned by co .Exploratory research, drug discovery and early development will be led by Agios.  Full Article

Agios Pharmaceuticals announces data from ongoing phase 1 Trial of AG-120
Saturday, 5 Dec 2015 

Agios Pharmaceuticals:Says new data from the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced hematologic malignancies.The data are being presented at the 2015 American Society of Hematology Annual Meeting and Exposition (ASH) taking place December 5-8, 2015 in Orlando.AG-120 is being developed in collaboration with Celgene.  Full Article

BRIEF-Agios presents updated phase 1 data from dose expansion cohort of ivosidenib

* Agios presents updated phase 1 data from dose expansion cohort of ivosidenib (AG-120) in patients with IDH1 mutant positive glioma